At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 185 enrolled
Drug / intervention
5 mg Serlopitant Tablets +1 moredrug
Likely dose
5 mg Serlopitant Tabletsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough
In Brief
A Phase 2 clinical trial evaluating 5 mg Serlopitant Tablets and Matching Placebo Tablets for Refractory Chronic Cough. Completed, enrolled 185 participants across 39 sites in 2 countries.
Detailed Summary
Study of the efficacy, safety, and tolerability of serlopitant for the treatment of refractory chronic cough
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRefractory Chronic Cough
CountriesUnited Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedSep 2017
Enrollment StartOct 2017
Primary CompletionAug 2018
Study CompletionSep 2018
TodayJul 2026
First PostedSep 14, 2017
Enrollment StartOct 3, 2017
Primary CompletionAug 15, 2018
Study CompletionSep 6, 2018
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 8.8 years ago
Interventions
5 mg Serlopitant Tabletsdrug
Serlopitant Tablets
Matching Placebo Tabletsdrug
Placebo Tablets